The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 21, 2025
Filed:
Jan. 03, 2019
Applicant:
Nantbio, Inc., Culver City, CA (US);
Inventor:
Kayvan Niazi, Culver City, CA (US);
Assignee:
NantBio, Inc., Culver City, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 40/42 (2024.12); A61K 35/17 (2014.12); A61K 38/17 (2005.12); A61K 40/15 (2024.12); A61K 40/32 (2024.12); A61K 45/06 (2005.12); C07K 14/725 (2005.12); C12N 5/0783 (2009.12); C12N 15/62 (2005.12); A61K 48/00 (2005.12);
U.S. Cl.
CPC ...
A61K 38/1774 (2012.12); A61K 35/17 (2012.12); A61K 40/15 (2024.12); A61K 40/32 (2024.12); A61K 40/428 (2024.12); A61K 45/06 (2012.12); C07K 14/7051 (2012.12); C12N 5/0646 (2012.12); C12N 15/62 (2012.12); A61K 48/00 (2012.12); C12N 2510/00 (2012.12);
Abstract
Compositions, methods and uses of genetically modified NK cells to treat a patient with a tumor are presented. The genetically modified NK cells express a protein complex having an α chain and a β chain T cell receptor, at least a portion of which is specific to a patient- or tumor-specific neoepitope, or a tumor associated antigen, and at least a portion of CD3δ, and at least a portion of CD3γ. The genetically modified NK cells can be administered to a cancer patient to induce, maintain or augment a T cell immune response against the cancer or the tumor.